Akorn Hit With Derivative Suit Over $4.3B Fresenius Deal
Generic-drug maker Akorn Inc. and its board members were hit with a putative class action filed by stockholders in Illinois county court Tuesday, accusing the board of undercutting the stockholders' profits...To view the full article, register now.
Already a subscriber? Click here to view full article